241 related articles for article (PubMed ID: 24525130)
21. A novel biphenyl urea derivate inhibits the invasion of breast cancer through the modulation of CXCR4.
Zhan Y; Zhang H; Li J; Zhang Y; Zhang J; He L
J Cell Mol Med; 2015 Jul; 19(7):1614-23. PubMed ID: 25753200
[TBL] [Abstract][Full Text] [Related]
22. Regulation of crosstalk between epithelial to mesenchymal transition molecules and MMP-9 mediates the antimetastatic activity of anethole in DU145 prostate cancer cells.
Ha B; Ko H; Kim B; Sohn EJ; Jung JH; Kim JS; Yoon JJ; Won G; Kim JH; Jung DB; Yun M; Shim B; Kim SH
J Nat Prod; 2014 Jan; 77(1):63-9. PubMed ID: 24328151
[TBL] [Abstract][Full Text] [Related]
23. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
Cai F; Zhang Y; Li J; Huang S; Gao R
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440
[TBL] [Abstract][Full Text] [Related]
24. Differential role of PTEN in transforming growth factor β (TGF-β) effects on proliferation and migration in prostate cancer cells.
Kimbrough-Allah MN; Millena AC; Khan SA
Prostate; 2018 Apr; 78(5):377-389. PubMed ID: 29341212
[TBL] [Abstract][Full Text] [Related]
25. [P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer].
Wang YX; Shi YH; Gong LH; Li Y; Heng WJ; You JF; Zhong HH; Fang WG
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):681-6. PubMed ID: 18194602
[TBL] [Abstract][Full Text] [Related]
26. Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity.
Hjelmeland AB; Hjelmeland MD; Shi Q; Hart JL; Bigner DD; Wang XF; Kontos CD; Rich JN
Cancer Res; 2005 Dec; 65(24):11276-81. PubMed ID: 16357132
[TBL] [Abstract][Full Text] [Related]
27. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
[TBL] [Abstract][Full Text] [Related]
28. Suppressing the formation of lipid raft-associated Rac1/PI3K/Akt signaling complexes by curcumin inhibits SDF-1α-induced invasion of human esophageal carcinoma cells.
Lin ML; Lu YC; Chen HY; Lee CC; Chung JG; Chen SS
Mol Carcinog; 2014 May; 53(5):360-79. PubMed ID: 23192861
[TBL] [Abstract][Full Text] [Related]
29. SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
Uygur B; Abramo K; Leikina E; Vary C; Liaw L; Wu WS
Prostate; 2015 Jun; 75(9):907-16. PubMed ID: 25728608
[TBL] [Abstract][Full Text] [Related]
30. Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
Dixon KM; Lui GY; Kovacevic Z; Zhang D; Yao M; Chen Z; Dong Q; Assinder SJ; Richardson DR
Br J Cancer; 2013 Feb; 108(2):409-19. PubMed ID: 23287991
[TBL] [Abstract][Full Text] [Related]
31. Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation.
Gwak HS; Park MJ; Park IC; Woo SH; Jin HO; Rhee CH; Jung HW
J Neurosurg; 2014 Dec; 121(6):1483-91. PubMed ID: 25303017
[TBL] [Abstract][Full Text] [Related]
32. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
33. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways.
Park CM; Park MJ; Kwak HJ; Lee HC; Kim MS; Lee SH; Park IC; Rhee CH; Hong SI
Cancer Res; 2006 Sep; 66(17):8511-9. PubMed ID: 16951163
[TBL] [Abstract][Full Text] [Related]
34. Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway.
Kong L; Schäfer G; Bu H; Zhang Y; Zhang Y; Klocker H
Carcinogenesis; 2012 Apr; 33(4):751-9. PubMed ID: 22301279
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):239-47. PubMed ID: 21816290
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival.
Wegiel B; Bjartell A; Culig Z; Persson JL
Int J Cancer; 2008 Apr; 122(7):1521-9. PubMed ID: 18027847
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol induces cell cycle arrest in human gastric cancer MGC803 cells via the PTEN-regulated PI3K/Akt signaling pathway.
Jing X; Cheng W; Wang S; Li P; He L
Oncol Rep; 2016 Jan; 35(1):472-8. PubMed ID: 26530632
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
39. Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells.
Ghalali A; Wiklund F; Zheng H; Stenius U; Högberg J
Carcinogenesis; 2014 Jul; 35(7):1547-55. PubMed ID: 24451147
[TBL] [Abstract][Full Text] [Related]
40. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
Sengupta S; Schiff R; Katzenellenbogen BS
Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
